Acquisition of pylarify.

Ended Awarded Last action

Contract number
HT001426FE078
Awardee
Awarding agency
Obligated
$249,002

Award facts

Contract value 100% obligated
$249,001.68 Current and potential, with all options
Completion date
Current and potential, with all options
Contracting staff
NAICS code
325412 Pharmaceutical Preparation Manufacturing
PSC
6515 Medical And Surgical Instruments, Equipment, And Supplies
Competition
Full and Open Competition Multiple Award, Fair Opportunity
Pricing
Firm Fixed Price
Place of performance
Bethesda, MD 20889, USA

Award details come from SAM.gov/FPDS.

About this award

Written by GovTribe AI ·

The Defense Health Agency issued a BPA call to Lantheus Medical Imaging, Inc. for the acquisition of PYLARIFY with a ceiling value of $249,001.68, awarded on August 10, 2026. The call was issued under the Pharmaceuticals and Drugs GSA Schedule (FSS-61-IB). Place of performance is Bethesda, Maryland. PYLARIFY (piflufolastat F-18) is a radioactive diagnostic imaging agent used in positron emission tomography scans for prostate cancer detection and localization. The ultimate completion date is August 10, 2026, with firm fixed-price terms.

Quick answers

Who was awarded contract HT001426FE078?

HT001426FE078 was awarded to Lantheus Medical Imaging, Inc. by Defense Health Agency (Department of Defense) on August 10, 2026.

How much is contract HT001426FE078 worth?

The government has obligated $249,002 on HT001426FE078.

Is contract HT001426FE078 an order under another contract?

Yes. HT001426FE078 is a BPA call under V797P2234D-HT001423A0010, a blanket purchase agreement, on Pharmaceuticals and Drugs (FSS-61-IB).

Was contract HT001426FE078 competed?

The extent of competition for HT001426FE078 was full and open competition.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login